Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Durvalumab +/- Tremelimumab in Locally Advanced RCC
NCT02762006Phase 1Completed
- Start
- Dec 2016
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in renal cell carcinoma (RCC) (4 cohorts). Primary endpoint: Dose Limiting Toxicity up to 12 months. Started Dec 2016; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02762006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762006.